Clinical Trials
14 trialsNCT07459751 2026-03-10
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting
NCT03178552 2026-03-09
B-FAST
Hoffmann-La Roche
Phase 2/3 Active not recruiting
NCT06319313 2024-03-20
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc.
Phase 2/3 Not yet recruiting
NCT05427383 2023-12-19
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Shanghai JMT-Bio Inc.
Phase 2/3 Recruiting
NCT05001724 2023-04-25
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2/3 Terminated
NCT05661240 2022-12-22
Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields (EFE-P100)Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1(PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 2/3 Unknown
NCT01905657 2021-10-06
MK-3475-010
Merck Sharp & Dohme LLC
Phase 2/3 Completed
NCT03288870 2020-10-29
DOMINUS
Biocad
Phase 2/3 Unknown
NCT01774578 2020-05-28
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Lumos Pharma
Phase 2/3 Terminated
NCT02651610 2017-07-11
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Peregrine Pharmaceuticals
Phase 2/3 Withdrawn
NCT01348126 2015-11-05
GALAXY
Synta Pharmaceuticals Corp.
Phase 2/3 Terminated
NCT00261703 2012-05-11
Docetaxel in Head and Neck Cancer
Sanofi
Phase 2/3 Completed
NCT00401323 2011-01-20
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sanofi
Phase 2/3 Completed
NCT00043576 2009-03-12
ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
Novacea
Phase 2/3 Unknown